🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — February 27, 2026

Across 23 filings from the USA S&P 500 Healthcare stream (with some adjacent financials/REITs), dominant themes include neutral board departures (5/23 filings, e.g., Lifeward, Pulse Biosciences, Western New England), Nasdaq compliance threats in biotechs (4/23, Jupiter Neurosciences, Ensysce Biosciences, CIMG, Avidity Biosciences), and limited financial disclosures showing one standout positive (Precipio's 30% YoY revenue growth to $24M, EBITDA inflection to +$1.23M). Period-over-period trends are sparse but highlight Precipio's outperformance with 23% Q4 revenue growth and positive adjusted EBITDA ($0.95M vs $0.40M prior), contrasting Disc Medicine's negative restructuring (20% workforce cut, $2M Q1 charges post-FDA setback). Capital allocation features steady dividends (Triumph Financial $0.44525/depositary share payable Mar 30) and ATM equity raises (Bridgewater $50M, FrontView $75M), signaling liquidity needs amid compliance risks. Portfolio-level patterns reveal biotech vulnerability to delisting (materiality 9/10 average), mixed AGM support (Jewett-Cameron), and high-risk M&A/change-of-control (Avidity). Most critical: Biotech delisting cascades could pressure sector liquidity; actionable now via short-term trades on compliance deadlines (Aug 2026) and Precipio's April catalyst.

11 high priority 12 medium 23 total filings
· daily

Global High-Priority Regulatory Events — February 27, 2026

Across 140 filings centered on February 27, 2026, dominant themes include robust debt refinancing and issuance activity (e.g., Wyndham $650M notes, WESCO $1.5B at lower 5.25-5.50% rates vs prior 7.25%), SPAC IPOs and business combinations (e.g., Clearthink $125M, Mozayyx $261M, IQM/RAAQ quantum computing deal), and frequent executive changes/departures (neutral in 20+ cases like Tandem, Iridium, Western New England). Bearish pressures from Nasdaq delisting/deficiency notices (9 cases: Datavault, reAlpha, Envoy, Jupiter, Ensysce, Tenon, CIMG) and insolvencies (10+ medium-risk, mostly Indian firms like Heranba, Reliance). Warner Bros. Discovery's 10-K shows revenue -5% YoY to $37.3B but operating income turnaround from -$10B loss to $738M profit, with Streaming EBITDA +102% to $1.37B; no broad PoP trends but aggregate capital raises exceed $5B+. Media M&A peaks with PSKY $81B WBD takeover (7.5x 2026 EBITDA) and Netflix $2.8B termination fee. Portfolio implication: Favor liquidity-strong firms amid small-cap listing risks; watch Q3 2026 deal closes.

140 high priority 140 total filings
· daily

US Earnings Financial Results SEC Filings — February 27, 2026

Warner Bros. Discovery's 2025 10-K filing reveals a mixed performance with total revenues declining 5% YoY to $37.3B amid sharp drops in Global Linear Networks (-12%), advertising (-10%), and content (-6%), underscoring the structural decline in legacy TV and ad markets. However, the company staged a dramatic profitability turnaround, swinging to operating income of $738M from a $10.0B loss and net income available to WBD of $727M from an $11.3B loss, driven by Streaming revenues +5% YoY, Studios +9% YoY, and Streaming Adjusted EBITDA surging to $1,370M from $677M. Cost efficiencies were pivotal, with impairments/losses on dispositions plummeting 98% to $172M and depreciation/amortization down 19% to $5,684M, though total Adjusted EBITDA dipped 3% to $8.7B. This reflects a broader media sector pivot to streaming amid cord-cutting pressures, positioning WBD as a turnaround story but with ongoing legacy revenue risks. Mixed sentiment (10/10 materiality) signals investor caution on growth sustainability versus profitability gains. Portfolio-level insight from this sole filing highlights media companies' need for aggressive cost cuts to offset revenue headwinds, creating selective buy opportunities in streaming-focused names.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — February 27, 2026

Across 39 SEC 8-K filings on February 27, 2026, focused on US executive and director changes, the dominant theme is neutral leadership transitions with 18 resignations/retirements (all citing no disagreements with operations/policies), 10 appointments of experienced directors/executives, and 11 compensatory arrangements signaling retention efforts amid stable governance. Positive outliers include strategic hires like Northpointe Bancshares' ex-Comptroller Rodney Hood and Childrens Place's retail veteran Kim Roy, alongside compensation expansions such as Ambarella's 28% larger FY2027 bonus pool and Lesaka Technologies' salary hikes (e.g., CEO base to $503K). No explicit period-over-period financial trends (YoY/QoQ revenue/margins) are broadly disclosed, but comp increases proxy management confidence in 2026 performance targets like revenue and EBITDA goals. Portfolio-level patterns show banking sector churn (7/39 filings: retirements/appointments at Popular, BancFirst, Ohio Valley, Western New England, Northpointe) suggesting routine board refresh, while healthcare (5 filings) and tech (8 filings) exhibit similar neutral stability. Market implications favor monitoring Q1 2026 10-Qs for comp exhibit details and AGMs for board impacts, with low overall materiality (avg 5/10) implying minimal near-term volatility but opportunities in underfollowed hires.

39 high priority 39 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — February 27, 2026

Across 64 8-K filings in the USA Corporate Distress & Bankruptcy intelligence stream on Feb 27, 2026, dominant themes include proactive debt refinancings and equity offerings amid liquidity pressures, with 25+ companies announcing new notes, amendments, or credit facilities (e.g., Wyndham $650M at 5.625%, WESCO $1.5B at 5.25-5.50%) to repay higher-cost debt, signaling managed distress rather than acute insolvency. However, 8 companies face critical Nasdaq compliance failures, including delisting notices (Datavault AI, reAlpha Tech, Envoy Medical) and bid price deficiencies below $1.00 for 30+ days (Jupiter Neurosciences, Ensysce, Tenon Medical), heightening bankruptcy risks for micro-caps. No explicit YoY/QoQ revenue declines noted, but distressed financing terms proliferate: 28.6% discount on IMAC $175k note, 15% OID on Kinetic Seas $148.5k note, vs. investment-grade refis like Royal Caribbean $2.5B at 4.75-5.25%. Capital allocation tilts to debt repayment (e.g., Fold Holdings extinguished $66.3M notes) and working capital, with positive outliers like Sphere 3D regaining compliance. Portfolio-level: small-cap biotech/tech (15/64) shows 60% negative/mixed sentiment on compliance woes; broader market access to capital mitigates systemic distress. Actionable implication: short delisting risks, long refi beneficiaries with lower rates improving D/E ratios.

64 high priority 64 total filings
· daily

US SEC Trading Suspension Halt Orders — February 27, 2026

Across 8 8-K filings in the USA Trading Suspensions stream, a pervasive theme of Nasdaq Capital Market compliance failures dominates, with 7/8 companies facing negative developments including minimum bid price deficiencies below $1.00 for 30 consecutive business days (Jupiter Neurosciences, Ensysce Biosciences, Tenon Medical), MVLS shortfalls below $35M (Jupiter), late 10-Q filings (CIMG), and outright delisting notices (Datavault AI, reAlpha Tech, Envoy Medical), signaling acute liquidity and visibility risks. Sphere 3D stands out positively, regaining bid price compliance after a year-long issue resolved as of Feb 26, 2026. No period-over-period financial trends, insider trading activity, capital allocation details, guidance changes, or operational metrics were disclosed in any filing, focusing intelligence purely on regulatory halts and delisting trajectories. Portfolio-level implications include heightened delisting cascade risks for microcap biotech, AI/tech, and medtech names, with 180-day compliance windows clustering around Aug 24-25, 2026, potentially triggering trading suspensions or OTC transfers that erode 50-90% of value historically. Common pattern: trading remains uninterrupted short-term, but failure rates exceed 60% for bid price cures without reverse splits. Investors face immediate action needs to trim exposure amid zero offsetting positives like insider buys or dividend hikes.

8 high priority 8 total filings
· daily

US Corporate Board Director Changes SEC Filings — February 27, 2026

Across 36 SEC 8-K filings dated February 27, 2026, focused on USA Board Room Changes, the dominant theme is elevated executive and board churn with 18 resignations/retirements (mostly planned, no disagreements cited) and 12 appointments/promotions, signaling routine refreshment amid neutral sentiment in 85% of cases. Positive signals emerge from compensation expansions (e.g., Ambarella's FY2027 bonus pool 28% larger YoY, Lesaka's CEO salary to $503K) and high-profile hires (e.g., Northpointe's ex-regulator Rodney Hood, Aurora's ex-Meta CFO David Wehner), indicating retention efforts in growth sectors like fintech and tech. No broad period-over-period financial deteriorations noted, but unknown details in 11 Item 5.02 filings (e.g., Trimas, Smurfit Westrock) raise opacity risks; forward-looking comp plans target 2026 performance with upside to 200% bonuses. Financials/banks show highest volume (9 filings), suggesting sector-wide governance tuning ahead of AGMs. Portfolio implications: leadership stability generally intact, but monitor small caps (materiality 7-9/10) for execution risks; actionable alpha in comp hikes signaling management conviction.

36 high priority 36 total filings
· daily

US Merger & Acquisition SEC Filings — February 27, 2026

A surge in SPAC activity dominates the 9 filings from February 27, 2026, with 3 new SPAC IPOs raising a combined $586M ($125M Clearthink, $261M MOZAYYX upsized, $200M TRG Latin America), signaling robust investor appetite for blank-check companies targeting financial services, general M&A, and Latin America. De-SPAC progress is evident in Real Asset Acquisition Corp.'s definitive agreement with IQM Finland for quantum computing (potential Nasdaq listing) and Voyager Acquisition Corp.'s merger approval with VERAXA Biotech (Nasdaq: VRXA post-close). Avidity Biosciences reports a completed takeover with change of control, delisting, and agreement termination, marking a rare public-to-private shift. Vague filings from Abony, Roman DBDR, and Miluna highlight undisclosed M&A or governance events amid neutral sentiment. No period-over-period financial trends available across filings, but transaction volumes indicate heightened M&A momentum in tech/biotech/SPACs versus subdued traditional M&A. Capital allocation absent; forward-looking catalysts include IPO closings Feb 25-27, 2026, and conference calls. Implications: SPAC IPO boom offers entry points for merger arbitrage, while delisting/takeover in Avidity flags liquidity risks.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — February 27, 2026

Across 94 overnight SEC 8-K filings from Feb 26-27, 2026, the dominant theme is a surge in earnings-related disclosures (approx. 40 filings with Item 2.02), signaling peak earnings season with neutral sentiment in all cases due to undisclosed quantitative metrics like YoY/QoQ revenue growth or margins. A notable cluster of 15+ material definitive agreements (Item 1.01) points to heightened M&A activity across sectors like pharma, energy, and tech, potentially indicating consolidation plays though terms remain undisclosed. No insider trading activity, capital allocation details (dividends/buybacks), or forward-looking guidance changes are disclosed in any filing, limiting precise trend synthesis; however, period-over-period comparisons are absent across the board. One critical bearish outlier: Datavault AI Inc. delisting notice (materiality 10/10). Portfolio-level patterns show pharma/biotech (12+ filings) and energy/funds (15+) leading volume, with overall low-medium risk and neutral-to-mixed sentiment implying stable but opaque pre-market positioning. Actionable implication: Monitor exhibits/press releases for hidden beats/misses in high-materiality earnings (avg materiality 6-8/10); M&A clusters offer alpha if accretive.

21 high priority 73 medium 94 total filings
· daily

Biotech Small-Cap Approvals — February 26, 2026

A cluster of 5 approvals for BRIVARACETAM (1 bullish, 4 neutral ANDAs) signals intensifying generic competition, likely eroding pricing for originators while enabling portfolio expansion for small-cap generics firms. Vanda Pharms' NME approval for milsaperidone stands out as a high-potential novel asset with exclusivity. Neutral overall due to unspecified indications across 7/8 records, limiting market sizing; no risks beyond routine generic pressures.

8 total filings
· daily

New Drug Approvals (Original) — February 26, 2026

A cluster of five Brivaracetam approvals (one bullish original for Hainan Poly, four neutral ANDAs) signals imminent generic erosion in the US market, pressuring originator revenues while enabling volume-driven growth for generic sponsors. Bullish catalysts include Vanda Pharms' NME approval for milsaperidone and Hainan Poly's Brivaracetam nod, marking rare novel entries amid seven standard-review approvals. Neutral impacts dominate from unspecified indications across all records, limiting precise market sizing but highlighting generic portfolio expansions for Asian and specialty firms.

8 total filings
· daily

Federal Professional Services Contracts — February 26, 2026

Ameresco Inc. won a $217M firm fixed-price GSA delivery order for 19-year deep energy retrofits at 25 federal buildings in Region 5, signaling strong federal commitment to energy savings programs. This provides long-term revenue stability with $11.8M in options, but execution risks loom due to the extended timeline and no initial outlays. Investors should view this as a bullish catalyst for energy services firms targeting government contracts.

1 total filings
· daily

All NASA Contracts — February 26, 2026

A single $138.8M NASA contract to ALCYON TECHNICAL SERVICES (ATS) JV, LLC for facilities support and logistics at Glenn Research Center shows steady execution with $66M outlayed over 10+ years but signals neutral investment outlook due to high subcontractor reliance (56% of value) and nearing end in March 2026. Risks center on execution variability in cost-plus structure and dependency on 952 subawards totaling $77.9M. Opportunities include ~$7M in unobligated options and potential follow-ons for ongoing NASA needs.

1 total filings
· daily

S&P 500 Energy Sector SEC Filings — February 26, 2026

A cluster of five 8-K filings on February 26, 2026, primarily from S&P 500 Energy sector players (Cheniere Energy, Cheniere Energy Partners, Targa Resources) alongside outliers Papa Johns and CommScope, reveals standard earnings-related disclosures under Items 2.02 and 9.01 with uniformly neutral sentiment and low risk levels. No period-over-period comparisons, quantitative financial metrics, insider trading activity, forward-looking guidance, capital allocation details, or transaction data are disclosed in summaries, limiting granular trend analysis but suggesting stable operations without major surprises. Materiality scores range from 3/10 (Targa) to 8/10 (CommScope), with energy filers averaging 5/10, indicating moderate investor attention required. Portfolio-level, energy subsector shows synchronized routine disclosures absent deteriorating trends or bullish catalysts, implying sector stability amid potential exhibit-driven insights. Cross-company patterns highlight absence of red flags like guidance cuts or insider sales, but lack of enriched quantitative data flags assessment gaps. Market implications: Neutral setup favors review of attached financial statements/exhibits for hidden alpha before catalysts like earnings calls.

5 medium 5 total filings
· daily

HHS & Healthcare Contracts Intelligence — February 25, 2026

HHS BARDA's $110.9M obligated contract (potential $299M total) to small biotech MAPP Biopharmaceutical provides multi-year R&D funding for Marburg virus immunotherapy MBP091, with $53.8M already outlayed since 2022 award. This bullish signal underscores government prioritization of biodefense countermeasures amid single-contract concentration in biotech. Monitor option exercises for 170% upside and funding continuity risks over 10+ year horizon.

1 total filings
· daily

Big Pharma Approvals — February 24, 2026

Three Big Pharma Approval records from February 24, 2026, yielded exclusively neutral signals for AstraZeneca's Acalabrutinib (including maleate form) and AbbVie's Venetoclax, with no risks, opportunities, or key points identified. This one-day snapshot reveals no material regulatory catalysts, indicating a quiet period absent portfolio-impacting developments. Investors should maintain current positions absent further data.

3 total filings
· daily

Defense Manufacturing Contracts — February 23, 2026

Eastern Shipbuilding Group secured a $1.4B Coast Guard OPC shipbuilding contract (potential $1.71B with options), signaling strong long-term revenue for this small business amid defense manufacturing priorities. Minimal $448k outlay to date versus massive obligation highlights execution risks over the 13-year term to 2027. Investors should monitor subawards ($429M across 709) for supply chain opportunities in shipbuilding.

1 total filings